| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christoffer Clemmensen, Sanela Smajilovic, Eric P Smith, Stephen C Woods, Hans Bräuner-Osborne, Randy J Seeley, David A D'Alessio, Karen K Rya. Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice. Endocrinology. vol 154. issue 11. 2014-01-08. PMID:23959939. |
importantly, recent evidence suggests the amino acid l-arginine, a well-known insulin secretagogue, can also stimulate release of glp-1 from isolated rat intestine. |
2014-01-08 |
2023-08-12 |
mouse |
| Christoffer Clemmensen, Sanela Smajilovic, Eric P Smith, Stephen C Woods, Hans Bräuner-Osborne, Randy J Seeley, David A D'Alessio, Karen K Rya. Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice. Endocrinology. vol 154. issue 11. 2014-01-08. PMID:23959939. |
here we tested the hypothesis that oral l-arginine acts as a glp-1 secretagogue in vivo, to augment postprandial insulin secretion and improve glucose tolerance. |
2014-01-08 |
2023-08-12 |
mouse |
| Christoffer Clemmensen, Sanela Smajilovic, Eric P Smith, Stephen C Woods, Hans Bräuner-Osborne, Randy J Seeley, David A D'Alessio, Karen K Rya. Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice. Endocrinology. vol 154. issue 11. 2014-01-08. PMID:23959939. |
in both lean and obese mice oral l-arginine increased plasma glp-1 and insulin and substantially improved glucose clearance. |
2014-01-08 |
2023-08-12 |
mouse |
| Camilla Kappe, Qimin Zhang, Jens J Holst, Thomas Nyström, Ake Sjöhol. Evidence for paracrine/autocrine regulation of GLP-1-producing cells. American journal of physiology. Cell physiology. vol 305. issue 10. 2014-01-06. PMID:23986202. |
secretion of glp-1 has been suggested to be impaired in t2d and in conditions associated with hyperlipidemia and insulin resistance. |
2014-01-06 |
2023-08-12 |
Not clear |
| Camilla Kappe, Qimin Zhang, Jens J Holst, Thomas Nyström, Ake Sjöhol. Evidence for paracrine/autocrine regulation of GLP-1-producing cells. American journal of physiology. Cell physiology. vol 305. issue 10. 2014-01-06. PMID:23986202. |
however, little is known about the regulation of l-cell viability/function, the effects of insulin signaling, or the potential effects of stable glp-1 analogs and dipeptidyl peptidase-4 (dpp-4) inhibitors. |
2014-01-06 |
2023-08-12 |
Not clear |
| Camilla Kappe, Qimin Zhang, Jens J Holst, Thomas Nyström, Ake Sjöhol. Evidence for paracrine/autocrine regulation of GLP-1-producing cells. American journal of physiology. Cell physiology. vol 305. issue 10. 2014-01-06. PMID:23986202. |
we determined effects of insulin as well as possible autocrine action of glp-1 on viability/apoptosis of glp-1-secreting cells in the presence/absence of palmitate, while also assessing direct effects on function. |
2014-01-06 |
2023-08-12 |
Not clear |
| Camilla Kappe, Qimin Zhang, Jens J Holst, Thomas Nyström, Ake Sjöhol. Evidence for paracrine/autocrine regulation of GLP-1-producing cells. American journal of physiology. Cell physiology. vol 305. issue 10. 2014-01-06. PMID:23986202. |
insulin/exendin-4 also significantly stimulate acute and long-term glp-1 secretion in the presence of glucose, suggesting novel beneficial effects of insulin signaling and glp-1r activation on glycemia through enhanced mass of glp-1-producing cells and enhanced glp-1 secretion. |
2014-01-06 |
2023-08-12 |
Not clear |
| Camilla Kappe, Qimin Zhang, Jens J Holst, Thomas Nyström, Ake Sjöhol. Evidence for paracrine/autocrine regulation of GLP-1-producing cells. American journal of physiology. Cell physiology. vol 305. issue 10. 2014-01-06. PMID:23986202. |
in addition, the effects of insulin indicate that not only is glp-1 important for insulin secretion but altered insulin signaling may contribute to an altered glp-1 secretion. |
2014-01-06 |
2023-08-12 |
Not clear |
| Takayuki Shida, Noriyasu Kamei, Mariko Takeda-Morishita, Koichi Isowa, Kozo Takayam. Colonic delivery of docosahexaenoic acid improves impaired glucose tolerance via GLP-1 secretion and suppresses pancreatic islet hyperplasia in diabetic KK-A(y) mice. International journal of pharmaceutics. vol 450. issue 1-2. 2013-12-31. PMID:23618969. |
glucagon-like peptide-1 (glp-1) is an incretin hormone that regulates the insulin secretion depending on blood glucose level. |
2013-12-31 |
2023-08-12 |
mouse |
| Takayuki Shida, Noriyasu Kamei, Mariko Takeda-Morishita, Koichi Isowa, Kozo Takayam. Colonic delivery of docosahexaenoic acid improves impaired glucose tolerance via GLP-1 secretion and suppresses pancreatic islet hyperplasia in diabetic KK-A(y) mice. International journal of pharmaceutics. vol 450. issue 1-2. 2013-12-31. PMID:23618969. |
we have shown previously that docosahexaenoic acid (dha) and eicosapentaenoic acid (epa) administered into a mouse closed intestinal loop, especially into the colonic segment, stimulate glp-1 and insulin secretion and have a hypoglycemic effect, suggesting that dha and epa have potential as antidiabetic agents. |
2013-12-31 |
2023-08-12 |
mouse |
| R Balena, I E Hensley, S Miller, A H Barnet. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes, obesity & metabolism. vol 15. issue 6. 2013-12-30. PMID:23061470. |
combination therapy with glp-1 receptor agonists and basal insulin: a systematic review of the literature. |
2013-12-30 |
2023-08-12 |
Not clear |
| Meng Zhang, Yang Feng, Jia Wang, Jianwei Zhao, Ting Li, Min He, Dehua Yang, Olivier Nosjean, Jean Boutin, Pierre Renard, Ming-Wei Wan. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice. PloS one. vol 8. issue 5. 2013-12-30. PMID:23704946. |
it is involved in glucose-stimulated insulin secretion and glucagon-like peptide-1 (glp-1) release, thereby representing a promising target for the treatment of type 2 diabetes. |
2013-12-30 |
2023-08-12 |
mouse |
| Meng Zhang, Yang Feng, Jia Wang, Jianwei Zhao, Ting Li, Min He, Dehua Yang, Olivier Nosjean, Jean Boutin, Pierre Renard, Ming-Wei Wan. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice. PloS one. vol 8. issue 5. 2013-12-30. PMID:23704946. |
exposure of min6 and glutag cells to mw1219 enhanced glucose-stimulated insulin secretion and glp-1 release; once-daily oral dosing of mw1219 for 6 weeks in diabetic db/db mice reduced hemoglobin a1c (hba1c) and improved plasma glucose, insulin and glp-1 levels; it also increased glucose tolerance. |
2013-12-30 |
2023-08-12 |
mouse |
| Susan S Schiffman, Kristina I Rothe. Sucralose, a synthetic organochlorine sweetener: overview of biological issues. Journal of toxicology and environmental health. Part B, Critical reviews. vol 16. issue 7. 2013-12-30. PMID:24219506. |
both human and rodent studies demonstrated that sucralose may alter glucose, insulin, and glucagon-like peptide 1 (glp-1) levels. |
2013-12-30 |
2023-08-12 |
human |
| b' Molly G Minze, Mary S Klein, Michelle J Jernigan, Stephen L Wise, Kristian Frug\\xc3\\xa. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus. Pharmacotherapy. vol 33. issue 6. 2013-12-27. PMID:23553357.' |
once-weekly exenatide, an extended-duration glucagon-like peptide-1 (glp-1) agonist, provides an option for patients to take a drug weekly, with pharmacotherapeutic effects that are superior to twice-daily exenatide and sitagliptin and comparable to insulin glargine. |
2013-12-27 |
2023-08-12 |
Not clear |
| Wakaya Fujiwara, Hideo Izawa, Gen Ukai, Hiroatsu Yokoi, Daisuke Mukaide, Kohsuke Kinoshita, Shin-ichiro Morimoto, Junichi Ishii, Yukio Ozaki, Masanori Nomur. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart and vessels. vol 28. issue 3. 2013-12-23. PMID:22447467. |
at baseline, there were no differences in age, body mass index, systolic blood pressure (sbp), and diastolic blood pressure (dbp), as well as plasma levels of hemoglobin a1c, insulin, low-density lipoprotein cholesterol, triglycerides, adiponectin, resistin, and active glp-1 between the two groups. |
2013-12-23 |
2023-08-12 |
Not clear |
| Wakaya Fujiwara, Hideo Izawa, Gen Ukai, Hiroatsu Yokoi, Daisuke Mukaide, Kohsuke Kinoshita, Shin-ichiro Morimoto, Junichi Ishii, Yukio Ozaki, Masanori Nomur. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart and vessels. vol 28. issue 3. 2013-12-23. PMID:22447467. |
there were no changes of the glucose and lipid profiles, including adiponectin, resistin, insulin, and active glp-1 levels after 24 weeks of treatment in both groups. |
2013-12-23 |
2023-08-12 |
Not clear |
| M Berkelaar, E M W Eekhoff, A M C Simonis-Bik, D I Boomsma, M Diamant, R G Ijzerman, J M Dekker, L M 't Hart, E J C de Geu. Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control. Diabetologia. vol 56. issue 6. 2013-12-23. PMID:23404443. |
we also examined whether experimentally induced increases in insulin by beta cell secretagogues, including glucagon-like peptide-1 (glp-1), will decrease vagal control. |
2013-12-23 |
2023-08-12 |
Not clear |
| P Valensi, S Chiheb, M Fysekidi. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia. vol 56. issue 6. 2013-12-23. PMID:23584434. |
glp-1 infusion during hyperglycaemia increased hr and bp and produced a statistically non-significant decrease in measures of cardiac vagal control compared with values before any manipulation of insulin levels. |
2013-12-23 |
2023-08-12 |
human |
| P Valensi, S Chiheb, M Fysekidi. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia. vol 56. issue 6. 2013-12-23. PMID:23584434. |
this commentary summarises how, and to what extent, insulin and glp-1 affect autonomic nervous system activity, hr and bp. |
2013-12-23 |
2023-08-12 |
human |